According to the Zhitong Finance App, Elken Healthcare (01789) announced its 2017 results, achieving revenue of about RMB 373 million (same unit below), up 37.6% year on year; gross profit of about 264 million yuan, up 40.8% year on year; the company's equity shareholders should account for about 105 million yuan in profit during the year, up 36.3% year on year; profit of 0.14 yuan per share, with a proposed final dividend of HK3.5 per share.

The announcement said the growth was mainly driven by strong sales performance of joint replacement implants, including 3D printed products. 3D printing products achieved revenue of 33.4 million yuan during the year, an increase of 175.7% over the previous year. This increase was mainly due to the fact that 3D printed products were the only 3D printed orthopedic products to obtain a registration certificate in China. Once the products were launched, they were highly recognized by the market, and sales grew rapidly.